DEPLIPIDO Study: Functional and Lipidomic Analysis of Plasma HDL in Patients With Depression Compared to Controls (DepLIPIDO)

Depression is a disabling condition in terms of psychosocial alteration and also in terms of physical comorbidities. Depression doubles the risk of myocardial infarction compared with the general population, and this cardiovascular comorbidity leads to an increase in mortality in patients suffering from depression, even exceeding suicide-related mortality.

It is therefore important to better understand the mechanisms linking depression and cardiovascular disease.

Among the hypotheses that may account for the increased cardiovascular risk in patients with depression, lipid abnormalities are likely to play a crucial role.

Thus, qualitative and functional abnormalities in HDL lipoproteins are an important line of research, insofar as these lipid abnormalities have been recognized as important atherogenic abnormalities in populations at high cardiovascular risk, which is the case of patients with depression.

In this clinical, epidemiological and scientific context, a collaborative study undertaken by both the Department of Psychiatry of the Dijon Bourgogne University Hospital of and the INSERM LNC-UMR 1231 (PADYS) Laboratory of the UNIVERSITY OF BOURGOGNE FRANCHE-COMTE is an original translational research project, and the first study to perform a lipidomic analysis of HDL, coupled with a functional analysis of these lipoproteins in depression.

Study Overview

• Status: Recruiting
• Conditions: Depression
• Intervention / Treatment: Other: HDRS-17 depression scale; Biological: Blood sampling

• Study Type: Interventional
• Enrollment (Estimated): 90
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Jean-Christophe CHAUVET-GELINIER; Phone Number: 03 80 29 37 69; Email: jean-christophe.chauvet-gelinier@chu-dijon.fr

Study Locations

• France
  • Dijon, France, 21000
    • Recruiting
    • CHU Dijon Bourgogne
    • Contact: Jean-Christophe CHAUVET-GELINIER; Phone Number: 03 80 29 37 69; Email: jean-christophe.chauvet-gelinier@chu-dijon.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• FOR PATIENTS WITH RECURRENT DEPRESSION :

  • Patient who has provided oral consent
  • Adult with moderate to severe depression according to DSM-5 criteria (Hamilton HDRS-17 score ≥ 18), with a number of depressive episodes ≥ 3

• PATIENTS PRESENTING WITH A FIRST DEPRESSIVE EPISODE

  • Patient who has provided oral consent
  • Adult with moderate to severe characterized depression according to DSM-5 criteria (Hamilton HDRS-17 scale score ≥ 18) presenting with a first depressive episode.

• CONTROLS

  • Person who has provided oral consent
  • Adult who has never shown signs of depression

Exclusion Criteria:

• Person not affiliated with national health insurance
• Person subject to a measure of legal protection (curatorship, guardianship)
• Pregnant or breastfeeding women
• Adult unable to express consent
• Minors
• Person with a metabolic syndrome (according to NCEP/ATP-III criteria: 3 of the following 5 criteria: Waist circumference ≥ 102 cm in males and ≥ 88cm in females, Triglycerides > 1.50 g/L, HDL-Cholesterol < 0.40 g/L in H, HDL-Cholesterol < 0.50 g/L in F, Blood pressure ≥130/85mmHg, Fasting blood glucose ≥ 1.10 g/L),
• Person with type 1 or type 2 diabetes,
• Person with a mild depressive episode (HDRS-17<18),
• Person with concomitant antipsychotic treatment
• Person with bipolar disorder,
• Person with a moderate to severe alcohol use disorder according to DSM-5 criteria
• Person with schizophrenia,
• Person with a persistent delusional disorder,
• Person with an autism spectrum disorder.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Patients with recurrent depression with a number of depressive episodes ≥ 3	Other: HDRS-17 depression scale; Measuring the severity of depression; Biological: Blood sampling; 3 tubes of 5 ml
Experimental: Patients with a first depressive episode	Other: HDRS-17 depression scale; Measuring the severity of depression; Biological: Blood sampling; 3 tubes of 5 ml
Active Comparator: Healthy, non-depressed subjects	Other: HDRS-17 depression scale; Measuring the severity of depression; Biological: Blood sampling; 3 tubes of 5 ml

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Measurement of cholesterol efflux by fluorescent method on THP-1 cell derived macrophages	At baseline

Collaborators and Investigators

• Sponsor: Centre Hospitalier Universitaire Dijon

Study record dates

Study Major Dates

• Study Start (Actual): October 1, 2021
• Primary Completion (Estimated): October 1, 2027
• Study Completion (Estimated): October 1, 2027

Study Registration Dates

• First Submitted: October 4, 2021
• First Submitted That Met QC Criteria: October 18, 2021
• First Posted (Actual): October 29, 2021

Study Record Updates

• Last Update Posted (Estimated): September 12, 2025
• Last Update Submitted That Met QC Criteria: September 8, 2025
• Last Verified: September 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Behavioral Symptoms; Behavior; Depression; Investigative Techniques; Therapeutics; Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Blood Specimen Collection; Phlebotomy
• Other Study ID Numbers: CHAUVET CRBFC-E 2019

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No